Summit Financial’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Summit Financial’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.71M	Buy	+185,915	New	+$7.48M	0.08%	250

Other funds holding FTXH

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.44B AUM 38.08% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.38B AUM 24% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Benjamin Edwards Inc Clayton, Missouri $11.1B AUM 12.46% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

Daymark Wealth Partners Cincinnati, Ohio $4.41B AUM 22.52% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Summit Financial's FTXH Position: Q3 2026 in Review

Summit Financial opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2026: 185,915 shares worth $7.71M. The stake represents 0.08% of the portfolio and ranks #250 among its holdings.

48 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.

Summit Financial held 185,915 shares of First Trust Nasdaq Pharmaceuticals ETF worth $7.71M as of Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF was a new Summit Financial position in Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF made up 0.08% of Summit Financial's portfolio in Q3 2026, its #250 holding.
48 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.

Based on Summit Financial's 13F filing for Q3 2026, filed 12 Nov 2026.